We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Takeda (TAK) a Profitable Stock for Value Investors Now?
Read MoreHide Full Article
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Takeda Pharmaceutical Company Limited (TAK - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Takeda has a trailing twelve months PE ratio of 8.22, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.53. If we focus on the long-term PE trend, Takeda’s current PE level puts it below its midpoint over the past five years.
Further, the stock’s PE compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 20.01. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Takeda has a forward PE ratio (price relative to this year’s earnings) of just 11.17, which is tad higher than the current level. So it is fair to expect an increase in the company’s share price in the near term.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Takeda has a P/S ratio of about 2.68. This is lower than the S&P 500 average, which comes in at 3.11 right now. Also, as we can see in the chart below, this is below the highs for this stock in particular over the past few years.
If anything, TAK is in the higher end of its range in the time period from a P/S metric, suggesting some level of overvalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Takeda currently has a Zacks Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Takeda a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the P/CF ratio comes in at 7.62, which is lower than the industry average of 10.28. Clearly, TAK is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Takeda might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of A. This gives TAK a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been encouraging. The current year has seen one estimate go higher in the past sixty days compared to one lower, while the full year 2020 estimate has seen one upward revision compared to no downward in the same time period.
This has had a positive impact on the consensus estimate though as the current year consensus estimate has increased more than 100% in the past two months, while the full year 2020 estimate has increased more than 100%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Despite this positive trend, the stock has a Zacks Rank #3 (Hold), which indicates expectations of in-line performance from the company in the near term.
Bottom Line
Takeda is an inspired choice for value investors, as it is hard to beat its incredible line up of statistics on this front. A strong industry rank (among top 35% of more than 250 industries) further instils our confidence.
However, a Zacks Rank #3 makes it hard to get too excited about this company overall. In fact, over the past two years, the Zacks Medical - Drugs industry has clearly underperformed the market at large, as you can see below:
So, value investors might want to wait for industry trends to turn favorable in this name first, but once that happens, this stock could be a compelling pick.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Is Takeda (TAK) a Profitable Stock for Value Investors Now?
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Takeda Pharmaceutical Company Limited (TAK - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Takeda has a trailing twelve months PE ratio of 8.22, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.53. If we focus on the long-term PE trend, Takeda’s current PE level puts it below its midpoint over the past five years.
Further, the stock’s PE compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 20.01. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Takeda has a forward PE ratio (price relative to this year’s earnings) of just 11.17, which is tad higher than the current level. So it is fair to expect an increase in the company’s share price in the near term.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Takeda has a P/S ratio of about 2.68. This is lower than the S&P 500 average, which comes in at 3.11 right now. Also, as we can see in the chart below, this is below the highs for this stock in particular over the past few years.
If anything, TAK is in the higher end of its range in the time period from a P/S metric, suggesting some level of overvalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Takeda currently has a Zacks Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Takeda a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the P/CF ratio comes in at 7.62, which is lower than the industry average of 10.28. Clearly, TAK is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Takeda might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of A. This gives TAK a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been encouraging. The current year has seen one estimate go higher in the past sixty days compared to one lower, while the full year 2020 estimate has seen one upward revision compared to no downward in the same time period.
This has had a positive impact on the consensus estimate though as the current year consensus estimate has increased more than 100% in the past two months, while the full year 2020 estimate has increased more than 100%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Takeda Pharmaceutical Co. Price and Consensus
Takeda Pharmaceutical Co. price-consensus-chart | Takeda Pharmaceutical Co. Quote
Despite this positive trend, the stock has a Zacks Rank #3 (Hold), which indicates expectations of in-line performance from the company in the near term.
Bottom Line
Takeda is an inspired choice for value investors, as it is hard to beat its incredible line up of statistics on this front. A strong industry rank (among top 35% of more than 250 industries) further instils our confidence.
However, a Zacks Rank #3 makes it hard to get too excited about this company overall. In fact, over the past two years, the Zacks Medical - Drugs industry has clearly underperformed the market at large, as you can see below:
So, value investors might want to wait for industry trends to turn favorable in this name first, but once that happens, this stock could be a compelling pick.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>